Premium
The influence of the novel 5‐HT 1A agonist R137696 on the proximal stomach function in healthy volunteers
Author(s) -
Boeckxstaens G. E.,
Tytgat G. N.,
Wajs E.,
Van Nueten L.,
De Ridder F.,
Meulemans A.,
Tack J.
Publication year - 2006
Publication title -
neurogastroenterology and motility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.489
H-Index - 105
eISSN - 1365-2982
pISSN - 1350-1925
DOI - 10.1111/j.1365-2982.2006.00812.x
Subject(s) - gastric distension , distension , barostat , medicine , placebo , nausea , agonist , stomach , tegaserod , visual analogue scale , anesthesia , irritable bowel syndrome , receptor , pathology , alternative medicine
As fundic dysaccommodation represents one of the pathophysiological mechanisms underlying functional dyspepsia, gastric relaxant agents may serve as a new treatment of this disorder. Previous studies have suggested the involvement of 5HT 1 receptors in the control of gastric tone. Our aim was to study the effect of R137696, a novel 5HT 1A agonist, on fundus sensorimotor function in healthy volunteers. The effect of single oral doses (1–2 mg) R137696 was evaluated in a double‐blind, placebo‐controlled manner on fasting fundic volume, visceral perception, distension‐evoked symptoms and fundic compliance in 21 healthy male subjects. R137696 increased the proximal stomach volumes in a dose‐dependent manner. Distention‐evoked symptoms or distention and discomfort threshold were not altered by R137696. A logistic regression model, characterizing the relationships between the volume and the visual analogue scale score for dyspeptic symptoms (nausea, fullness, discomfort, pain and satiety) as a sigmoidal curve, revealed that R137696 had no effect on distension‐induced discomfort, fullness, pain and satiety compared to placebo. R137696 relaxes the gastric fundus in fasting conditions but has no effect on distension‐evoked dyspeptic symptoms in healthy volunteers.